A pharmacophore model for PDE IV inhibitors

Quantitative Structure-Activity Relationships

Volumn 16, Issue 3, 1997, Pages 231-234

  Polymeropoulos, Emmanuel E ^a   Höfgen, Norbert ^a  

^a ASTA MEDICA AG   (Germany)

Author keywords

Asthma; GRID calculations; Molecular modelling; Nitraquazone analogs; PDE IV inhibitors; Pharmacophore; Rolipram analogs; Xanthine analogs

Indexed keywords

BINDING SITES; PHARMACODYNAMICS;

ASTHMA; CONFORMATIONAL ANALYSIS; GRID CALCULATION; NITRAQUAZONE ANALOG; PDE IV INHIBITOR; PHARMACOPHORE MODELS; PHARMACOPHORES; ROLIPRAM ANALOG; STRUCTURAL DIFFERENCES; XANTHINE ANALOG;

HYDROGEN BONDS;

DRUG CARRIER; NITRAQUAZONE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; ROLIPRAM DERIVATIVE; XANTHINE DERIVATIVE;

ARTICLE; BINDING SITE; CALCULATION; CONFORMATION; ENZYME BINDING; HYDROGEN BOND; PRIORITY JOURNAL;

EID: 1842333864     PISSN: 09318771     EISSN: None     Source Type: Journal    
DOI: 10.1002/qsar.19970160307     Document Type: Article

References (18)

1. Palfreyman, M.N., Drugs Future 20, 793-804 (1995).
2. Palacios, J.M., Beleta, J. and Segarra, V., II Farmaco 50, 819-827 (1995).
3. Torphy, T.J., Stadel, J.M., Burman, M., Cieslinski, L.B., McLaughlin, M.M., White, J.R. and Livi, J.P., J. Biol. Chem. 267, 1798-1804 (1992).
4. Schmiechen, R., Schneider, H.H. and Wachtel, H., Psychopharmacology 102, 17-20 (1990).
5. Barnette, M.S., Torphy, T.J. and Christensen, S.B., Compounds, WO 00139, (1995).
6. Inhibition of PDE IV in human PMNL. Assay established at ASTA/ AWD.
7. Cavalla, D. and Frith, R., Curr. Med. Chem. 2, 561-572 (1995).
8. Stafford, J.A., Veal, J.M., Feldman, P.L., Valvano, N.L., Baer, P.G., Brackeen, M.F., Sloan Brawley, E., Connolly, K.M., Domanico, P.L., Han, B., Rose, D.A., Rutkowske, R.D., Sekut, L., Stimpson, S.A., Strickland, A.B. and Verghese, M.W., J. Med. Chem. 38, 4972-4975 (1995).
9. Brackeen, M.F., Cowan, D.J., Stafford, J.A., Schoenen, F.J., Veal, J.M., Domanico, P.L., Rose, D., Strickland, A.B., Verghese, M. and Feldman, P.L., J. Med. Chem. 38, 4848-1854 (1995).
10. Duplantier, A.J., Biggers, M.S., Chambers, R.J., Cheng, J.B., Cooper, K., Damon, D.B., Eggler, J.F., Kraus, K.G., Marfat, A., Masamune, H., Pillar, J.S., Shirley, J.T., Umland, J.P. and Watson, J.W., J. Med. Chem. 39, 120-125 (1996).
11. MDL Drug Data Report (MDDR).
12. Buckle, D.R., Arch, J.R., Connolly, B.J., Fenwick, A.E., Foster, K.A., Murray, K.J., Readshaw, S.A., Smallridge, M. and Smith, D.G., J. Med. Chem. 37, 476-485 (1994).
13. Goodford, P.J., J. Med. Chem. 28, 849-857 (1985).
14. Marivet, M.C., Bourguignon, J.J., Lugnier, C., Mann, A., Stoclet, J.C. and Wermuth, C.G., J. Med. Chem. 32, 1450-1457 (1989).
15. AM1; MOPAC v.5.0, QCPE, No. 455, 1989.
16. Baures, P.W., Eggleston, D.S., Erhard, K.F., Cieslinski, L.B., Torphy, T.J. and Christensen, S.B., J. Med. Chem. 36, 3274-3277 (1993).
17. Third International Conference on Cyclic Nucleotide Phosphodiesterases: From Genes to Therapies, Glasgow.
18. Brickmann, J. and Waldherr-Teschner, M., Informationstechnik 2, 83-90 (1991).